Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody

Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody

Background This study evaluated the efficacy and safety of retreatment with anti‐programmed death 1 (anti‐PD‐1) antibodies in patients with advanced non‐small cell lung cancer (NSCLC) after prior treatment with anti‐programmed death‐ligand 1 (anti‐PD‐L1) antibodies. Methods Data (N = 15) on patients...

Full description

Bibliographic Details
Main Authors:	Kohei Fujita, Yuki Yamamoto, Osamu Kanai, Misato Okamura, Masayuki Hashimoto, Koichi Nakatani, Satoru Sawai, Tadashi Mio
Format:	Article
Language:	English
Published:	Wiley 2020-01-01
Series:	Thoracic Cancer
Subjects:	Anti‐PD‐1 anti‐PD‐L1 immune checkpoint inhibitors lung cancer retreatment
Online Access:	https://doi.org/10.1111/1759-7714.13241

Similar Items

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
by: Kazushige Yoshida, et al.
Published: (2020-01-01)

Real‐world efficacy of atezolizumab in non‐small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti‐PD‐1 antibody
by: Naoki Furuya, et al.
Published: (2021-03-01)

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer
by: Janice M. Mehnert, et al.
Published: (2019-03-01)

Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies
by: Giuseppe Bellastella, et al.
Published: (2021-08-01)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
by: Yaxiong Zhang, et al.
Published: (2018-12-01)

Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis
by: Andrea Botticelli, et al.
Published: (2021-08-01)

Anti‐PD1 versus anti‐PD‐L1 immunotherapy in first‐line therapy for advanced non‐small cell lung cancer: A systematic review and meta‐analysis
by: Angelo Borsarelli Carvalho Brito, et al.
Published: (2021-04-01)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
by: Mengke Niu, et al.
Published: (2021-03-01)

Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm
by: Martin Rao, et al.
Published: (2017-03-01)

Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy
by: Chunmeng Wang, et al.
Published: (2021-07-01)

Anti PD-1 protitelesa
by: Janja Ocvirk
Published: (2017-12-01)

Microsatellite instability status predicts response to anti-PD-1/PD-L1 therapy regardless the histotype: A comment on recent advances
by: Semir Vranic
Published: (2017-08-01)

Diffuse granulomatous panniculitis associated with anti PD-1 antibody therapy
by: Baijia Jiang, MD, et al.
Published: (2018-01-01)

Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies
by: Yumi Kambayashi, et al.
Published: (2019-07-01)

Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma
by: Yuyin Fu, et al.
Published: (2021-07-01)

Clinical Research Progress of Anti PD-1/PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
by: Zhiyu HUANG, et al.
Published: (2015-11-01)

Combination Treatment of Topical Imiquimod Plus Anti-PD-1 Antibody Exerts Significantly Potent Antitumor Effect
by: Kazumasa Oya, et al.
Published: (2021-08-01)

A T-cell-dependent antibody response study using a murine surrogate anti-PD-1 monoclonal antibody as an alternative to a non-human primate model
by: Lisa M. Plitnick, et al.
Published: (2020-01-01)

The Top 100 Most Frequently Cited Publications Concerning Anti-PD-1/PD-L1 Therapy for Lung Cancer: A Bibliometric Analysis
by: Li Y, et al.
Published: (2021-02-01)

Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies
by: Sonam Puri, et al.
Published: (2020-01-01)

Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations
by: Xiao-Dong Zhu, et al.
Published: (2021-03-01)

Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer
by: Yi Que, et al.
Published: (2021-07-01)

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2020-04-01)

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4<sup>+</sup> T Cells
by: Reem Saleh, et al.
Published: (2019-10-01)

Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28
by: Chaoxu Zhang, et al.
Published: (2020-05-01)

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
by: Alessio Cortellini, et al.
Published: (2019-02-01)

Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs
by: Sara Zalba, et al.
Published: (2020-06-01)

Safety and Efficacy of Anti-PD-1/PD-L1 Inhibitors Compared With Docetaxel for NSCLC: A Systematic Review and Meta-Analysis
by: Long Ma, et al.
Published: (2021-08-01)

Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers
by: Bo Yang, et al.
Published: (2018-11-01)

Organizing pneumonia after thoracic radiotherapy followed by anti‐PD‐1 antibody treatment for patients with lung cancer: Three case reports
by: Masakuni Sakaguchi, et al.
Published: (2019-06-01)

Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo
by: Xiaoqiang Liu, et al.
Published: (2019-12-01)

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
by: Andrea Botticelli, et al.
Published: (2018-08-01)

A Late Dermatologic Presentation of Bullous Pemphigoid Induced by Anti-PD-1 Therapy and Associated with Unexplained Neurological Disorder
by: Xiaoxiao Wang, et al.
Published: (2021-06-01)

Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications
by: Feifei Teng, et al.
Published: (2020-09-01)

Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies
by: Mariacarmela Santarpia, et al.
Published: (2020-06-01)

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
by: Edouard Dantoing, et al.
Published: (2021-06-01)

A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors
by: Xiao‐Li Wei, et al.
Published: (2020-08-01)

Identification of Potential Biomarkers for Anti-PD-1 Therapy in Melanoma by Weighted Correlation Network Analysis
by: Xuanyi Wang, et al.
Published: (2020-04-01)

Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study
by: Min Yuan, et al.
Published: (2021-10-01)

Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-γ-associated JAK-STAT pathway
by: Xue W, et al.
Published: (2019-03-01)